Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Stoke Therapeutics, Inc. Common Stock

STOK

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Last trade $26.32
Day change -$0.31 (-1.16%)
Day range $25.79 – $26.93
Volume 197,587
Market cap $1.74B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.74B
Price / earnings
—
Price / book
4.94×
Price / sales
61.74×
EV / sales
57.94×
EV / EBITDA
-6.38×

Profitability

Earnings per share
-$3.72
Return on assets
-59.8%
Return on equity
-68.98%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
7.24×
Quick ratio
7.24×
Cash ratio
2.19×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$187.66M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for STOK, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$11.26M$9.33M$6.23M$1.4M$10.63M$13.82M$158.57M$22.61M
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$11.26M$9.33M$6.23M$1.4M$10.63M$13.82M$158.57M$22.61M
Selling, general and administrative$28.74M$25.25M$19.97M$21.15M$16.03M$15.26M$14.65M$12.84M
Research and development$59.83M$49.5M$39.67M$41.7M$37.7M$25.86M$32.68M$23.42M
Total operating expenses$88.57M$74.75M$59.65M$62.84M$53.72M$41.12M$47.33M$36.27M
Operating income-$77.32M-$65.43M-$53.42M-$61.44M-$43.09M-$27.3M$111.24M-$13.65M
Interest expense-$20K$3.5M$0$0-$3K$3.79M$0$0
Income before taxes-$73.64M-$61.62M-$50M-$57.93M-$39.63M-$23.48M$114.16M-$10.48M
Income taxes$0$0$0$0-$1.28M$0$1.28M$0
Net income-$73.64M-$61.62M-$50M-$57.93M-$38.35M-$23.48M$112.88M-$10.48M
Net income attributable to common shareholders-$73.64M-$61.62M-$50M-$57.93M-$38.35M-$23.48M$112.88M-$10.48M
EBITDA-$76.86M-$65.43M-$52.98M-$61.03M-$42.65M-$27.3M$111.72M-$13.13M
Basic earnings per share-$1.08-$0.93-$0.79-$0.93-$0.65-$0.40$1.95-$0.18
Diluted earnings per share-$1.08-$0.93-$0.79-$0.96-$0.65-$0.40$1.90-$0.18

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates

Stoke Therapeutics reported a Q3 loss of $1.08 per share, missing consensus estimates of $0.88 loss by 22.73%, though the company exceeded revenue expectations with $11.26 million versus estimated $8.29 million. The stock has underperformed the S&P 500 by 29.9% year-to-date and carries a Zacks Rank #3 (Hold) rating with mixed estimate revisions.

Benzinga

A Closer Look at 5 Analyst Recommendations For Stoke Therapeutics

Ratings for Stoke Therapeutics (NASDAQ:STOK) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 3 0 0 0 0 3M Ago 1 0 0 0 0 Analysts have set 12-month price targets for Stoke Therapeutics, revealing an average target of $24.2, a high estimate of $35.00, and a low estimate of $20.00. Experiencing a 3.2% decline, the current average is now lower than the previous average price target of $25.00. Understanding Analyst Ratings: A Comprehensive Breakdown A clear picture of Stoke Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Joseph Stringer Needham Maintains Buy $22.00 $22.00 Andrew Fein HC Wainwright & Co. Maintains Buy $35.00 $35.00 Sumant Kulkarni Canaccord Genuity Lowers Buy $20.00 $21.00 Joseph Stringer Needham Maintains Buy $22.00 $22.00 Joseph Stringer Needham Maintains Buy $22.00 - Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their ...Full story available on Benzinga.com

Benzinga

Analyst Expectations For Stoke Therapeutics's Future

Stoke Therapeutics (NASDAQ:STOK) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 6 1 1 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 3 1 1 0 0 3M Ago 1 0 0 0 0 Analysts have recently evaluated Stoke Therapeutics and provided 12-month price targets. The average target is $20.75, accompanied by a high estimate of $35.00 and a low estimate of $13.00. Witnessing a positive shift, the current average has risen by 62.75% from the previous average price target of $12.75. Understanding Analyst Ratings: A Comprehensive Breakdown A comprehensive examination of how financial experts perceive Stoke Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Joseph Stringer Needham Maintains Buy $22.00 - Joseph Stringer Needham Maintains Buy $22.00 - Laura Chico Wedbush Raises Outperform $17.00 $13.00 Sumant Kulkarni Canaccord Genuity Raises Buy $21.00 $18.00 Jessica Fye JP Morgan Raises Neutral $13.00 $6.00 Andrew Fein HC Wainwright & Co. Maintains Buy $35.00 - Joseph Stringer Needham Raises Buy $22.00 $14.00 Joseph Stringer Needham Maintains Buy $14.00 - Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Stoke Therapeutics. This information ...Full story available on Benzinga.com

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.